SCHEMBL6077160

SCHEMBL6077160

O=C1CCCC12c1ccccc1CCc1ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.46
KDM1A O60341 4/20 0.42
TSHR P16473 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HTR2A P28223 2/20 0.41
CHRM2 P08172 1/20 0.40
ADRA2A P08913 1/20 0.40
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
GSK3A P49840 1/20 0.38
SLC6A4 P31645 2/20 0.38
GRIN1 Q05586 2/20 0.38
GRIN2A Q12879 2/20 0.38
OPRK1 P41145 1/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
LMNA P02545 1/20 0.38
OPRM1 P35372 1/20 0.38
GRIN2B Q13224 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13541879 0.87 AKR1B1 (0.40) AKR1B1KDM1ATSHRTDP1CHRM2
SCHEMBL3545440 0.79 GRIN1 (0.37) AKR1B1KDM1ASLC6A4GRIN1GRIN2A
SCHEMBL8054284 0.78 AKR1B1 (0.47) AKR1B1KDM1ATSHRTDP1HTR2A
SCHEMBL28498656 0.77 GRIN1 (0.45) KDM1ATDP1SLC6A4GRIN1GRIN2A
SCHEMBL31347965 0.77 TSHR (0.45) AKR1B1KDM1ATSHRTDP1HTR2A
SCHEMBL15003306 0.76 KDM1A (0.49) AKR1B1KDM1ATSHRHTR2AHTR2C
SCHEMBL3666780 0.74 MEN1 (0.47) OPRK1OPRM1
Hydrochloric Acid SCHEMBL6541839 0.73 KDM1A (0.46) AKR1B1KDM1ATSHRHTR2AHTR2C
SCHEMBL14544790 0.72 HTR2A (0.55) AKR1B1KDM1ATSHRTDP1HTR2A
SCHEMBL3549606 0.70 TDP1 (0.39) AKR1B1KDM1ATSHRTDP1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642283-B2 modulating the activity of the mitochrondrial permeability transition pore complex comprising exposing the complex to a compound such as 6-bromo-3-methylene-chroman-4-one HOFFMANN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-7642283-B2 modulating the activity of the mitochrondrial permeability transition pore complex comprising exposing the complex to a compound such as 6-bromo-3-methylene-chroman-4-one HOFFMANN-LA ROCHE INC. (US) 2010-01-05 US disclosed
EP-1468995-B1 MPTP affinity labels HOFFMANN LA ROCHE (CH) 2008-05-14 EP disclosed
US-7101917-B2 Mitochrondrial permeability transition pore affinity labels and modulators HOFFMANN-LA ROCHE INC. (US) 2006-09-05 US disclosed
US-20040220257-A1 Mitochrondrial permeability transition pore affinity labels and modulators HOFFMANN-LA ROCHE INC. 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220257-A1 Mitochrondrial permeability transition pore affinity labels and modulators MCU, ATP5PB, MFN2 AKR1B1 1925/4885KDM1A 4499/4885TSHR 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.